MSD to acquire EyeBio

Start-up developing new treatment options for patients with retinal diseases

03-Jun-2024 - Merck & Co., known as MSD outside of the United States and Canada, and EyeBiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ...

Eye color genes are critical for retinal health

Effect of kynurenine pathway on retinal health deciphered

27-Mar-2023 - Metabolic pathways consist of a series of biochemical reactions in cells that convert a starting component into other products. There is growing evidence that metabolic pathways coupled with external stress factors influence the health of cells and tissues. Many human diseases, including retinal ...

Rabbits' detached retina 'glued' with new hydrogel

14-Mar-2017 - A newly developed elastic gel administered in liquid form and shown to turn jellylike within minutes after injection into rabbits' eyes to replace the clear gelatinous fluid inside their eyeballs, may help pave the way for new eye surgery techniques, says an international team of researchers led ...

Fish eyes may hold key to regenerating human retinas

13-Mar-2017 - If you were a fish and your retina was damaged, it could repair itself and your vision would be restored in a few weeks. Sadly, human eyes don’t have this beneficial ability. However, new research into retinal regeneration in zebrafish has identified a signal that appears to trigger the ...

A closer look at the eye

04-Jan-2017 - Researchers at the University of Rochester Medical Center have developed a new imaging technique that could revolutionize how eye health and disease are assessed. The group is first to be able to make out individual cells at the back of the eye that are implicated in vision loss in diseases like ...

Stem cells derived from amniotic membrane can benefit retinal diseases when transplanted

Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration

21-Aug-2015 - A team of researchers in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy (a murine model used to mimic eye disease). The treatment aimed at ...

NIH launches research to gaze deeply into your eyes

Five projects pave the way for the audacious goal of restoring vision to the blind

05-May-2015 - Five bold projects will develop new technology to noninvasively image cells of the eye in unprecedented detail. The National Eye Institute (NEI) announced the awards as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the ...

Protein found in fat-derived stem cells could halt age-related retinal damage

19-Nov-2013 - A team of researchers from Gifu Pharmaceutical University andGifu University in Japan has published results demonstrating that a type of protein found in stem cells taken from adipose (fat) tissue can reverse and prevent age-related, light-induced retinal damage in a mouse model, offering hope ...

Molecular Partners: Results from Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema

23-Jan-2013 - Molecular Partners announced that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published in The American Journal of Ophthalmology (AJO). MP0112 was shown to be ...

Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

05-May-2011 - Allergan, Inc. and Molecular Partners AG announced that they have entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin® protein targeting VEGF under investigation for the treatment of retinal diseases.Under the agreement, Allergan obtains exclusive global rights ...